Glucose Injection (Baxter)

Pays: Nouvelle-Zélande

Langue: anglais

Source: Medsafe (Medicines Safety Authority)

Ingrédients actifs:

Glucose monohydrate 70%

Disponible depuis:

Baxter Healthcare Ltd

DCI (Dénomination commune internationale):

Glucose monohydrate 70%

Dosage:

70 %

forme pharmaceutique:

Solution for infusion

Composition:

Active: Glucose monohydrate 70%

Unités en paquet:

Bag, plastic, 500 mL

classe:

General sale

Type d'ordonnance:

General sale

Fabriqué par:

Baxter Healthcare Corporation

indications thérapeutiques:

Hypertonic infusion solutions are indicated: - As a source of energy incorporated with parenteral nutrition with minimal dilution effect - For use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) The alimentary tract cannot or should not be used b) Gastrointestinal absorption of protein is impaired c) Metabolic requirements for protein are substantially increased, as with extensive burns.

Descriptif du produit:

Package - Contents - Shelf Life: Bag, plastic, - 500 mL - 24 months from date of manufacture stored at or below 30°C

Date de l'autorisation:

1977-09-06

Résumé des caractéristiques du produit

NEW ZEALAND DATA SHEET
Glucose (Viaflex) Data Sheet 26 September 2019
Page 1 of 14
Baxter Healthcare Ltd
1 GLUCOSE INJECTION (BAXTER), (solution for infusion)
GLUCOSE Injection (Baxter)
5% solution for infusion
Glucose Injection (Baxter)
10% solution for infusion
Glucose Injection (Baxter)
25% solution for infusion
Glucose Injection (Baxter)
50% solution for infusion
Glucose Injection (Baxter)
70% solution for infusion
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
_Active ingredient _
The active ingredient is glucose (monohydrate).
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for infusion.
Glucose Injection (Baxter) are clear slightly coloured solutions for
intravenous (IV) infusion, in a
Viaflex® plastic bag.
The Glucose Injection (Baxter) infusion preparations are sterile,
non‐pyrogenic parenteral solutions.
They do not contain an antimicrobial agent or added buffer, and have a
pH of 3.5 ‐ 6.5 for 5% to 25%
glucose
concentrations,
and
a
pH
of
3.2
–
6.5
for
50%
to
70%
glucose
concentrations.
The
concentrations of glucose dissolved in a litre of Water for Injections
and their isotonicity are shown in
Tables 1 and 2 (see section 6.5).
The Glucose Injection (Baxter) 5% infusion is an _isotonic_ solution,
whereas Glucose Injection (Baxter)

10% infusions are _hypertonic_.
4 CLINICAL PARTICULARS
4.1
Therapeutic indications
Isotonic (Glucose Injection (Baxter) 5%) infusion solutions are mainly
indicated:

Whenever non‐electrolyte fluid replacement is required

As a vehicle for drug delivery, provided that the added components are
compatible with glucose.
Hypertonic (Glucose Injection (Baxter)

10%) infusion solutions are indicated:

As a source of energy incorporated with parenteral nutrition with
minimal dilution effect

For use with an appropriate protein (nitrogen) source in the
prevention of nitrogen loss or in the
treatment of negative nitrogen balance in patients where:
a)
the alimentary tract cannot or should not be used
b)
gastrointestinal absorption